Drug Profile

NYX 242

Alternative Names: NYX-242

Latest Information Update: 07 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nyrada
Class Neuroprotectants; Small molecules; Vascular disorder therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Stroke; Traumatic brain injuries

Most Recent Events

07 Aug 2024 NYX 242 is still in preclinical trials for Stroke and Traumatic brain injuries in Australia (Nyrada pipeline, August 2024)
28 Jul 2023 No recent reports of development identified for preclinical development in Stroke in Australia
28 Jul 2023 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in Australia

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com